Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
Cognitive impairment is a core symptom domain of schizophrenia. The effect of antipsychotics, the cornerstone of treatment in schizophrenia, on this domain is not fully clear. There is some evidence suggesting that antipsychotics may partially improve cognitive function, and that this improvement ma...
Main Authors: | Nicole E. MacKenzie, Chantel Kowalchuk, Sri Mahavir Agarwal, Kenya A. Costa-Dookhan, Fernando Caravaggio, Philip Gerretsen, Araba Chintoh, Gary J. Remington, Valerie H. Taylor, Daniel J. Müeller, Ariel Graff-Guerrero, Margaret K. Hahn |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-12-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2018.00622/full |
Similar Items
-
Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health
by: Nicolette Stogios, et al.
Published: (2021-04-01) -
Outcomes and clinical implications of intranasal insulin on cognition in humans: A systematic review and meta-analysis.
by: Sally Wu, et al.
Published: (2023-01-01) -
Metabolomic signatures associated with weight gain and psychosis spectrum diagnoses: A pilot study
by: Jiwon Lee, et al.
Published: (2023-04-01) -
Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial
by: Sri Mahavir Agarwal, et al.
Published: (2021-04-01) -
Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis
by: Pruntha Kanagasundaram, et al.
Published: (2021-03-01)